# BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

> **NCT00272779** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1057 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** ATV
- **DRUG:** RTV
- **DRUG:** Tenofovi-Emtricitabine (TDF/FTC) tablet
- **DRUG:** LPV

## Key facts

- **NCT ID:** NCT00272779
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-06
- **Final completion:** 2008-10
- **Target enrollment:** 1057 (ACTUAL)
- **Last updated:** 2011-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272779, "BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00272779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*